JP6321662B2 - Ｇｓｋ３阻害剤およびその使用の方法 - Google Patents

Ｇｓｋ３阻害剤およびその使用の方法 Download PDF

Info

Publication number
JP6321662B2
JP6321662B2 JP2015536972A JP2015536972A JP6321662B2 JP 6321662 B2 JP6321662 B2 JP 6321662B2 JP 2015536972 A JP2015536972 A JP 2015536972A JP 2015536972 A JP2015536972 A JP 2015536972A JP 6321662 B2 JP6321662 B2 JP 6321662B2
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
ring
membered saturated
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015536972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536307A (ja
JP2015536307A5 (enExample
Inventor
ワグナー，フローレンス，フェヴリエ
パン，ジェニファー，キュー．
ダンダパニ，シヴァラマン
ジェルマン，アンドリュー
ホルソン，エドワード
ムニョス，ベニート
ナグ，パーサ，ピー．
ウェイワー，ミシェル
ルイス，マイケル，シー．
ハガーティー，ステファン，ジェイ．
ビショップ，ジョシュア，エー．
ステグマイアー，キンバリー
バナージ，バーシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of JP2015536307A publication Critical patent/JP2015536307A/ja
Publication of JP2015536307A5 publication Critical patent/JP2015536307A5/ja
Application granted granted Critical
Publication of JP6321662B2 publication Critical patent/JP6321662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015536972A 2012-10-12 2013-10-11 Ｇｓｋ３阻害剤およびその使用の方法 Active JP6321662B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261713314P 2012-10-12 2012-10-12
US61/713,314 2012-10-12
US201361779394P 2013-03-13 2013-03-13
US61/779,394 2013-03-13
PCT/US2013/064716 WO2014059383A1 (en) 2012-10-12 2013-10-11 Gsk3 inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018072831A Division JP6606691B2 (ja) 2012-10-12 2018-04-05 Ｇｓｋ３阻害剤およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2015536307A JP2015536307A (ja) 2015-12-21
JP2015536307A5 JP2015536307A5 (enExample) 2016-12-22
JP6321662B2 true JP6321662B2 (ja) 2018-05-09

Family

ID=49474737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015536972A Active JP6321662B2 (ja) 2012-10-12 2013-10-11 Ｇｓｋ３阻害剤およびその使用の方法
JP2018072831A Active JP6606691B2 (ja) 2012-10-12 2018-04-05 Ｇｓｋ３阻害剤およびその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018072831A Active JP6606691B2 (ja) 2012-10-12 2018-04-05 Ｇｓｋ３阻害剤およびその使用の方法

Country Status (16)

Country Link
US (4) US9096594B2 (enExample)
EP (1) EP2909204B1 (enExample)
JP (2) JP6321662B2 (enExample)
CA (1) CA2887701C (enExample)
CY (1) CY1122601T1 (enExample)
DK (1) DK2909204T3 (enExample)
ES (1) ES2719776T3 (enExample)
HR (1) HRP20190406T1 (enExample)
HU (1) HUE043853T2 (enExample)
LT (1) LT2909204T (enExample)
PL (1) PL2909204T3 (enExample)
PT (1) PT2909204T (enExample)
RS (1) RS58700B1 (enExample)
SI (1) SI2909204T1 (enExample)
SM (1) SMT201900136T1 (enExample)
WO (1) WO2014059383A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
DK3702443T3 (da) 2013-03-14 2022-04-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
WO2016061344A1 (en) * 2014-10-15 2016-04-21 Mirx Pharmaceuticals Llc Gsk3 inhibitors and their uses
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
SG10201910821XA (en) 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
SG11201909115WA (en) 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
WO2018217766A1 (en) * 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
CN110407769B (zh) * 2018-04-27 2022-11-08 复旦大学 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途
CN112351819B (zh) 2018-06-05 2023-11-10 开动疗法公司 治疗恶性淋巴增生性疾病的方法
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
EP3837352A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2021102305A1 (en) * 2019-11-20 2021-05-27 Washington University Methods and compositions for generating functionally mature beta cells and uses thereof
WO2023056463A1 (en) * 2021-09-30 2023-04-06 Trustees Of Tufts College Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome
EP4601637A2 (en) * 2022-10-13 2025-08-20 The Broad Institute Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024259178A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
RO115162B1 (ro) 1993-04-08 1999-11-30 Du Pont Merck Pharma Derivati de compusi policiclici, compozitie farmaceutica ce contine acesti compusi si metoda de tratament
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP2005501800A (ja) * 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2450167A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
RU2006100484A (ru) * 2003-06-13 2006-06-10 Центарис ГмбХ, Германи (DE) Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках
EP1746097B1 (en) 2005-07-20 2010-01-13 Aventis Pharma S.A. 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
WO2010098888A1 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2014139870A (ja) * 2013-01-21 2014-07-31 Hitachi Consumer Electronics Co Ltd 照明装置およびこれを用いた映像表示装置
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
US10437707B2 (en) * 2015-03-19 2019-10-08 Teachers Insurance And Annuity Association Of America Evaluating and presenting software testing project status indicators
SG11201909115WA (en) 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Also Published As

Publication number Publication date
US10137122B2 (en) 2018-11-27
CY1122601T1 (el) 2021-03-12
US20190175584A1 (en) 2019-06-13
US20220160702A1 (en) 2022-05-26
JP2018150302A (ja) 2018-09-27
US20200061050A9 (en) 2020-02-27
US12419885B2 (en) 2025-09-23
EP2909204A1 (en) 2015-08-26
US9096594B2 (en) 2015-08-04
EP2909204B1 (en) 2018-12-05
WO2014059383A1 (en) 2014-04-17
PT2909204T (pt) 2019-03-21
JP2015536307A (ja) 2015-12-21
US20150313890A1 (en) 2015-11-05
HUE043853T2 (hu) 2019-09-30
CA2887701C (en) 2020-12-15
JP6606691B2 (ja) 2019-11-20
PL2909204T3 (pl) 2019-07-31
ES2719776T3 (es) 2019-07-16
CA2887701A1 (en) 2014-04-17
RS58700B1 (sr) 2019-06-28
DK2909204T3 (en) 2019-04-01
SMT201900136T1 (it) 2019-05-10
US11052080B2 (en) 2021-07-06
US20140107141A1 (en) 2014-04-17
HRP20190406T1 (hr) 2019-05-31
SI2909204T1 (sl) 2019-06-28
LT2909204T (lt) 2019-05-10

Similar Documents

Publication Publication Date Title
JP6606691B2 (ja) Ｇｓｋ３阻害剤およびその使用の方法
JP7157075B2 (ja) グリコーゲンシンターゼキナーゼ３（ｇｓｋ３）インヒビターとしての三環式化合物およびそれらの使用
US20160375006A1 (en) Uses of paralog-selective inhibitors of gsk3 kinases
KR20190075043A (ko) 비시클릭 우레아 키나제 억제제 및 그의 용도
KR20160111520A (ko) 디히드로프테리디논 유도체 및 그의 용도
JP2016505597A (ja) Ｐｒｍｔ５阻害剤およびその使用
JP2018526424A (ja) アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
JP2018526421A (ja) シアノチエノトリアゾロジアゼピンおよびこれらの使用
KR20170032474A (ko) 디히드로프테리디논 유도체 및 그의 용도
EP3052501A1 (en) Bicyclic alkyne derivatives and uses thereof
HK40013946A (en) Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
HK40013946B (en) Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
WO2024259178A1 (en) Glycogen synthase kinase 3 inhibitors and uses thereof
EP4601637A2 (en) Glycogen synthase kinase 3 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180405

R150 Certificate of patent or registration of utility model

Ref document number: 6321662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250